Fatigue Assessment Scale for IV Therapy Open Access Circle
This Circle utilizes a digitized version of the Fatigue Assessment Scale (FAS) validated outcome assessment. Follow up milestones include: baseline, 1-day, 3-day, 7-day, and 14-days following treatment. Circle members are invited to include up to 5 custom clinical questions to capture treatment-related data for research-related activities.
Determined by Investigator
- Obtain validated, longitudinal outcome scores measuring fatigue for patients receiving IV therpy.
- Evaluate IV therapy composition against patient-reported outcomes.
- Allow patients to visualize their personalized FAS scores upon entry.
Related Posts
Fatigue Assessment Scale for IV Therapy Open Access Circle
This Circle utilizes a digitized version of the Fatigue Assessment Scale (FAS) validated outcome assessment. Follow up milestones include: baseline, 1-day, 3-day, 7-day, and 14-days following treatment. Circle members are invited to include up to 5 custom clinical questions to capture treatment-related data for research-related activities.
FAS
- Obtain validated, longitudinal outcome scores measuring fatigue for patients receiving IV therpy.
- Evaluate IV therapy composition against patient-reported outcomes.
- Allow patients to visualize their personalized FAS scores upon entry.
Streamlined patient enrollment, real-world data capturing, heightened recognition, prominence and collaboration
CIRCLE LIBRARY
CIRCLE NAME
Total Knee Arthroplasty Outcome-Based Performance Measure
SURVEYS
VAS
KOOS Jr.
VR-12 (compliant with CMS/IQR Requirements)
As specified by Provider
THIS CIRCLE IS FOR:
Provider Receiving CMS Reimbursement For TKAs
CMS will soon penalize providers performing total knee replacements which do not collect specified outcomes data from at least 50% of qualifying patients.
Other Providers Performing TKAs
Private insurance companies and other payers within and outside the U.S. will follow the CMS lead in requiring high patient compliance in reporting long-term TKA outcomes.
WHY CIRCLES
If you have any questions, please contact us.